Revenue segments as reported by the company.

Product revenues, net

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development expenses

Acquired in-process research and development expenses

Selling, general and administrative expenses

Change in fair value of contingent consideration

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Vertex Pharmaceuticals

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Vertex Pharmaceuticals reports robust earnings, eyes growth in diverse therapies

Vertex Pharmaceuticals delivered strong financial results, provided optimistic revenue guidance for 2023, and emphasized investments in R&D and commercial capabilities. The company faces challenges with escalating costs and the need for clearer long-term financial goals. However, Vertex remains well-positioned to capitalize on growth opportunities in the healthcare market.

Vertex Pharmaceuticals reports robust Q1 growth and innovative pipeline

Vertex Pharmaceuticals had a strong Q1 2023 performance with revenue growth and ongoing investments in innovative therapies.
The company faces challenges in managing operating expenses and ensuring successful launches amidst competitive pressures.
However, Vertex's strengths lie in its diverse pipeline, regulatory approvals, and focus on transformative therapies.
Opportunities exist in addressing unmet medical needs, pursuing revenue growth in pain relief markets, and advancing non-opioid treatments.

Vertex Pharmaceuticals reports robust Q2 growth and pipeline advancements

Vertex Pharmaceuticals showed strong revenue growth and pipeline progress.
Challenges include slower uptake for gene therapies and market access.
Opportunities lie in reimbursement models, new therapy launches, and program advancements.
Overall, Vertex is strategically positioned for growth and innovation.

Vertex Pharmaceuticals reports strong Q3 growth and pipeline optimism

Vertex Pharmaceuticals shows solid financial performance and a robust pipeline of innovative therapies.
Challenges include navigating patient complexities, regulatory reviews, and market differentiation.
Opportunities lie in market expansion, therapeutic advancements, and strategic growth initiatives.
Overall, Vertex's focus on autonomy, innovation, and financial strength positions it for future success.

Vertex Pharmaceuticals reports robust Q4 earnings and strategic advancements

Vertex Pharmaceuticals delivered a strong performance in Q4 2023, driven by revenue growth, positive trial outcomes, and strategic advancements in its pipeline.
The company's focus on commercial diversification, regulatory approvals, and upcoming milestones in 2024 position Vertex well for continued success and growth.
While facing challenges related to patient targeting, physician capacity, and market differentiation, Vertex has opportunities to innovate, expand its reach, and enhance market positioning.
Overall, Vertex Pharmaceuticals' 2023 achievements, financial strength, and strategic initiatives underscore a promising outlook for the company's future growth and success.

Vertex Pharmaceuticals reports strong Q1 earnings and pipeline advancements

Vertex Pharmaceuticals demonstrated robust financial performance and strategic advancements in its pipeline and acquisitions, positioning itself for continued growth.
While facing challenges in commercialization and policy landscape, Vertex's strong financial position and innovative capabilities provide a solid foundation for future success.
With a focus on rare diseases, pain management, and revenue diversification, Vertex is poised to capitalize on market opportunities and drive innovation in healthcare.

Vertex Pharmaceuticals delivered strong revenue growth driven by key product demand, while facing increased operating expenses.
The company is focused on expanding its pipeline and accelerating new therapy launches amidst regulatory and commercial challenges.
Anticipation is high for upcoming launches like vanzacaftor and suzetrigine, signaling potential growth opportunities for Vertex.

Vertex Pharmaceuticals excels in Q3, poised for innovative growth

Vertex Pharmaceuticals demonstrated robust financial performance, highlighted by revenue growth and promising early launches. The company's strong R&D pipeline and strategic focus on commercialization underscore its commitment to driving innovation and growth. Addressing analyst inquiries and seizing growth opportunities will be key for Vertex's continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Eli Lilly

Regeneron Pharmaceuticals

Eli Lilly could be headed for a market capitalization above $1 trillion. Regeneron has overcome bumps and shows no signs of slowing down.

3 No-Brainer Stocks to Buy in July

Intellia Therapeutics

Let's get down to it: why should investors consider pharma stocks? Primarily, it comes down to the permanence of the underlying narrative.

3 Pharma Stocks Already Ushering in the Next Biotech Boom

Vertex has built an empire from cystic fibrosis treatment, generating billions of dollars in annual revenue. The company is set to dominate the market through the late 2030s -- and possibly beyond.

Prediction: This Will Be Vertex Pharmaceuticals' New Billion-Dollar Growth Driver (and It's Coming Soon).

Axsome Therapeutics

Investing in biotech can be pretty unpredictable. Biotech stocks are highly volatile, and picking carefully can be the difference between losing all your capital and making unimaginable profits.

The 3 Best Biotech Stocks to Buy in July 2024

Vertex Pharmaceuticals has significantly outpaced the market in the past few decades. The company owes its performance to a well-defined strategy and its innovative abilities.

1 Stock That Increased 10,000% in 33 Years to Buy and Hold Forever

Vertex Pharmaceuticals is working on a therapy to treat diabetes. The latest data about that therapy's performance looks solid.

Did Vertex Pharmaceuticals Just Invent the Next Ozempic?

Amgen

Viking Therapeutics

Amgen is much cheaper than Eli Lilly. Vertex Pharmaceuticals has several major growth drivers.

Forget Eli Lilly: 3 Biotech Stocks to Buy Instead

CRISPR Therapeutics

Schrodinger 

Gene editing utilizes enzymes that cut part of the DNA strand, allowing the insertion of replacement DNA. Several approaches to gene editing have been developed, the most well-known of which is CRISPR-Cas9.

3 Top-Rated Gene Editing Stocks Actually Making Money

The FDA accepts Vertex's (VRTX) new drug application for vanza triple therapy for people living with cystic fibrosis aged six years and above. A decision is due on Jan 2, 2025.

Vertex (VRTX) NDA for Vanza Triple Therapy Accepted by FDA

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for investigational once-daily vanzacaftor/tezacaftor/deutivacaftor triple combination therapy (vanza triple) for people living with cystic fibrosis (CF) ages 6 years and older who have at least one F508del mutation or another responsive mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) g.

Vertex Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-In-Class Triple Combination Treatment for Cystic Fibrosis

AbbVie

Pfizer

One of the most important sectors in any country's economy is the biotech sector. Picking under-the-radar biotech stocks is easier said than done because we do not see immediate results.

3 Under-the-Radar Biotech Stocks With Blockbuster Potential

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2024 financial results on Thursday, August 1, 2024 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the “Vertex Pharmaceuticals Second Quarter 2024 Earnings Call.” The conference call will be webcast live and a link to the webcast c.

Vertex to Announce Second Quarter 2024 Financial Results on August 1

Halozyme Therapeutics

Novo Nordisk

With the technology sector taking over in 2024, now is a great time to consider the best breakout biotech stocks to buy. Investing in these companies can be risky yet extremely rewarding, with careful selection of industry leaders.

3 Breakout Biotech Stocks on Track to Double by 2032

Spotify

The rare disease drug industry is fast-growing, while the music streaming space is also expanding at a rapid clip. Vertex is raking in profits from its cystic fibrosis drug franchise, but is also planning new additions to its portfolio.

2 Superior Growth Stocks to Buy if You Have $1,000 Right Now

Transmedics Group Inc

Vertex Pharmaceuticals could have multiple new blockbusters on the way. Viking Therapeutics is targeting two massive markets -- obesity and NASH.

Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030

A rare-disease drugmaker and a top pharmaceutical stock have what it takes to deliver solid returns over the long run. Vertex Pharmaceuticals' flagship business continues to expand market share and profits.

2 Healthcare Stocks That Are Screaming Buys in June

While CF remains the main area of focus, Vertex (VRTX) has seen rapid success in its non-CF pipeline candidates' development in the past year.

Vertex (VRTX) Rises 16.5% YTD: Time to Bet On the Stock?

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

This Vertex Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

In the world of investing, biotech stocks represent a unique blend of high risk and high reward. After a period of volatility in the broader markets in 2022 and 2023, biotech stocks are now drawing attention for their potential to deliver substantial long-term returns.

3 Biotech Stocks That Could Make Your Grandchildren Rich

Vertex Pharmaceuticals recently turned heads with clinical trial results for VX-880, an off-the-shelf cellular therapy for type 1 diabetes patients. Treatment with VX-880 helped patients produce insulin independently and reduced their reliance on daily injections.

Everyone's Talking About Vertex Pharmaceuticals. Is It Time to Buy?

Vertex Pharmaceuticals (VRTX) concluded the recent trading session at $474.95, signifying a +1.33% move from its prior day's close.

Vertex Pharmaceuticals (VRTX) Ascends While Market Falls: Some Facts to Note

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Here's Why Vertex Pharmaceuticals (VRTX) is a Strong Growth Stock

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today presented new data from its Phase 1/2 clinical trial of VX-880, an investigational stem cell-derived, fully differentiated islet cell therapy, in people with type 1 diabetes (T1D) with impaired hypoglycemic awareness and severe hypoglycemic events (SHEs). These updated data on 12 patients who received the full dose as a single infusion in Parts B and C of the trial are consistent with previously reported positive.

Vertex Announces Positive Results From Ongoing Phase 1/2 Study of VX-880 for the Treatment of Type 1 Diabetes Presented at the American Diabetes Association 84th Scientific Sessions

This magnificent drugmaker is much smaller than Eli Lilly, but is still large and successful. It has massive growth opportunities in multiple markets.

Forget Eli Lilly, Buy This Magnificent Biotech Stock Instead

In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $467.28, indicating a -1.35% shift from the previous trading day.

News for Vertex Pharmaceuticals Stock (VRTX)